AKT genetic aberrations that increase AKT activity have been detected in multiple malignancies and are especially common in breast cancer, where AKT3 amplification and AKT1 E17K oncogenic mutation have been reported in up to 24% and 1–8% of cases respectively [127,128,129]. This evidence concerns the gene AKT1 and breast carcinoma.